When AI designs a drug, who gets the credit?
Navigating the legal and ethical gray zones of algorithmic authorship in modern pharmaceutical research.
When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using A...
MIT Technology Review
Source

Generated insight by OnAirToday AI
The debate over AI-generated drug discovery challenges traditional intellectual property frameworks by blurring the lines between human innovation and machine-assisted output. Establishing clear credit is essential for future patent legitimacy and navigating the legal complexities of algorithmic authorship.

Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.